In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.

Medtech Insight spoke to two CEOs of start-ups working on graphene-based devices to learn more about how regulation and fears over nanomaterials’ side effects affect device development.

The biotech giant signed a commercial agreement with bioelectronics company Innervia, and the two will work collaboratively on vagus nerve stimulating technologies.